BLAINJECTIONINJECTABLEPriority Review
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADUHELM (aducanumab-avwa) is a monoclonal antibody developed by Biogen for early Alzheimer's disease. It targets amyloid-beta pathology in the brain via intravenous injection. The drug received accelerated FDA approval in June 2021 based on biomarker evidence, though clinical benefit remains controversial.
Peak
Product is in peak commercial phase but faces significant adoption headwinds due to clinical efficacy debates and reimbursement challenges, affecting team growth prospects.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
Started Nov 2021
29 enrolled
Alzheimers Disease
Career Relevance
ADUHELM offers career exposure to a high-complexity, controversial launch and the growing field of Alzheimer's disease treatment in neurology. Roles are heavily weighted toward managing reimbursement barriers, physician education, and real-world evidence generation rather than traditional commercial growth.
Brand Manager
Worked on ADUHELM at Biogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.